Abstract Details

Title Sociodemographic and Clinical Characteristics of Patients With Multiple Sclerosis by Race and Ethnicity (NARCRMS Registry)

Topic Health Care Disparities

Presentation(s) S18 - Health Care Disparities (4:00 PM-4:08 PM)

Poster/Presentation
Number 001

Objective To describe the sociodemographic and clinical characteristics of patients presenting with relapsing-remitting multiple sclerosis (MS) within the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) registry by race and ethnicity.

Background NARCRMS, a physician-based registry/longitudinal database for patients with MS (pwMS), may elucidate patient characteristics of underserved populations such as blacks/African Americans (AA) and Hispanics/Latinos.

Design/Methods The NARCRMS registry contains data of pwMS age 18-50 years across 24 sites from the US and Canada. This analysis describes characteristics of patients enrolled between December 2016 and May 2020 (N=722), including age, gender, education, income level and occupation, Expanded Disability Status Scale (EDSS) categories, and disease-modifying therapy (DMT) categories/DMT use. Patient characteristics were summarized by frequencies and proportions for categorical variables and by means and medians for continuous variables.

Results The mean age (SD) of patients was 40.1 (10.4) years; 71% were female. Majority (84%, n=587/695) were white Americans; black/AA patients comprised 11% (n=74/695). Despite comparable educational attainment between races, more black/AAs than white Americans were unemployed (8%, n=6/72 vs 3%, n=15/565) or had annual income <$15K (16%, n=12/73 vs 6%, n=35/573). Overall, 73% of patients had mild MS (EDSS scores 0?2.5). However, twice as many blacks/AAs had substantial disability (EDSS score ≥4.0) vs white Americans (21%, n=15/73 vs 10%, n=56/573, respectively). Over half of all patients (57%, n=370/646) were treated with DMTs?49% (n=182) using injectables and 37% (n=136) using oral DMTs. Hispanics, who comprised 24% (n=152/646) of the patients, were less likely than non-Hispanics to use DMTs, 43% (n=65/152) vs 62% (n=305/494). Of the subgroups, black/AA-Hispanics were least likely to use DMTs (26%, n=5/19).

Conclusions

Blacks/AAs present with more severe disability than white American patients. More Hispanics than non-Hispanics are not treated with DMTs. Real-world data show disparities in sociodemographic and clinical characteristics of pwMS.

Study Supported By: Biogen (Cambridge, MA, USA).

Authors/Disclosures
Victor M. Rivera, MD, FAAN (Baylor College of Medicine) PRESENTER	Dr. Rivera has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Rivera has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche Laboratories. Dr. Rivera has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for LACTRIMS. Dr. Rivera has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Central American Forum on MS. Dr. Rivera has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Bracken Law Firm, El Paso, TX.
Pavle Repovic, MD, PhD (Multiple Sclerosis Center)	Dr. Repovic has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela/Horizon. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Banner. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. Repovic has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ANI. Dr. Repovic has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Celgene/BristolMyersSquibb. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Repovic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Repovic has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Viela. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medison. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Repovic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon. The institution of Dr. Repovic has received research support from Genentech. The institution of Dr. Repovic has received research support from Biogen.
	No disclosure on file
	No disclosure on file
Coraly Perez Bajandas	Ms. Perez Bajandas has received personal compensation for serving as an employee of Biogen. Ms. Perez Bajandas has received stock or an ownership interest from Biogen.
Toni Saldana-King	Toni Saldana-King has received personal compensation for serving as an employee of Biogen. Toni Saldana-King has received stock or an ownership interest from Biogen.
Wanda Castro-Borrero, MD	Dr. Castro-Borrero has received personal compensation for serving as an employee of BIOGEN. Dr. Castro-Borrero has received stock or an ownership interest from BIOGEN.

��ɫ��

��ɫ��